The ITN will establish a study management team (SMT) with representation from each of its key operations, regulatory, and scientific groups, tasked with protocol development. As the Protocol Chair for this study, Dr. Levitsky is responsible for ensuring that the protocol developed by the team and submitted for review and approval is complete and consistent, methodologically sound, and directs study conduct to be in accord with all applicablem regulations and NIH/NIAID policy. Dr. Levitsky will be involved heavily in the Protocol Development phase. There will be regular Study Management Team (SMT) calls (the frequency--typically weekly--of these calls will be determined by the SMT). Protocol development may also require several in-person meetings which will be scheduled as needed.
|Effective start/end date||9/1/22 → 1/31/28|
- Benaroya Research Institute at Virginia Mason (FY22ITN580 // 5UM1AI109565-09)
- National Institute of Allergy and Infectious Diseases (FY22ITN580 // 5UM1AI109565-09)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.